Literature DB >> 30770516

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.

Kathleen M Andersen1,2, Ayano Kelly1,2, Anne Lyddiatt1,2, Clifton O Bingham1,2, Vivian P Bykerk1,2, Adena Batterman1,2, Joan Westreich1,2, Michelle K Jones1,2, Marita Cross1,2, Peter M Brooks1,2, Lyn March1,2, Beverley Shea1,2, Peter Tugwell1,2, Lee S Simon1,2, Robin Christensen1,2, Susan J Bartlett3,4.   

Abstract

OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.
METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.
RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.
CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

Entities:  

Keywords:  CLINICAL TRIALS; DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; DRUG TOXICITY; OMERACT; PATIENT SATISFACTION; RISK

Year:  2019        PMID: 30770516      PMCID: PMC6697626          DOI: 10.3899/jrheum.181185

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register.

Authors:  Lotta Gäwert; Franka Hierse; Angela Zink; Anja Strangfeld
Journal:  Rheumatology (Oxford)       Date:  2010-09-25       Impact factor: 7.580

3.  Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.

Authors:  Louise Klokker; Peter Tugwell; Daniel E Furst; Dan Devoe; Paula Williamson; Caroline B Terwee; Maria E Suarez-Almazor; Vibeke Strand; Thasia Woodworth; Amye L Leong; Niti Goel; Maarten Boers; Peter M Brooks; Lee S Simon; Robin Christensen
Journal:  J Rheumatol       Date:  2016-10-15       Impact factor: 4.666

Review 4.  Safety of treatment options for spondyloarthritis: a narrative review.

Authors:  Salvatore D'Angelo; Antonio Carriero; Michele Gilio; Francesco Ursini; Pietro Leccese; Carlo Palazzi
Journal:  Expert Opin Drug Saf       Date:  2018-03-14       Impact factor: 4.250

5.  The missing voice of patients in drug-safety reporting.

Authors:  Ethan Basch
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

6.  Facilitators and barriers to adherence in the initiation phase of Disease-modifying Antirheumatic Drug (DMARD) use in patients with arthritis who recently started their first DMARD treatment.

Authors:  Annelieke Pasma; Adriaan van 't Spijker; Jolanda J Luime; Margot J M Walter; Jan J V Busschbach; Johanna M W Hazes
Journal:  J Rheumatol       Date:  2014-12-15       Impact factor: 4.666

7.  Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Authors:  Maarten Boers; John R Kirwan; George Wells; Dorcas Beaton; Laure Gossec; Maria-Antonietta d'Agostino; Philip G Conaghan; Clifton O Bingham; Peter Brooks; Robert Landewé; Lyn March; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell
Journal:  J Clin Epidemiol       Date:  2014-02-28       Impact factor: 6.437

8.  Living with rheumatoid arthritis and experiencing everyday life with TNF-α blockers.

Authors:  Charlotte Lindén; Anita Björklund
Journal:  Scand J Occup Ther       Date:  2009-12-14       Impact factor: 2.611

9.  Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication.

Authors:  L J Goodacre; J A Goodacre
Journal:  Rheumatology (Oxford)       Date:  2004-02-17       Impact factor: 7.580

10.  Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.

Authors:  Anjan K Banerjee; Sally Okun; I Ralph Edwards; Paul Wicks; Meredith Y Smith; Stephen J Mayall; Bruno Flamion; Charles Cleeland; Ethan Basch
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

  10 in total
  3 in total

Review 1.  Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations.

Authors:  Bethea A Kleykamp; Robert H Dworkin; Dennis C Turk; Zubin Bhagwagar; Penney Cowan; Christopher Eccleston; Susan S Ellenberg; Scott R Evans; John T Farrar; Roy L Freeman; Louis P Garrison; Jennifer S Gewandter; Veeraindar Goli; Smriti Iyengar; Alejandro R Jadad; Mark P Jensen; Roderick Junor; Nathaniel P Katz; J Patrick Kesslak; Ernest A Kopecky; Dmitri Lissin; John D Markman; Michael P McDermott; Philip J Mease; Alec B O'Connor; Kushang V Patel; Srinivasa N Raja; Michael C Rowbotham; Cristina Sampaio; Jasvinder A Singh; Ilona Steigerwald; Vibeke Strand; Leslie A Tive; Jeffrey Tobias; Ajay D Wasan; Hilary D Wilson
Journal:  Pain       Date:  2021-09-09       Impact factor: 7.926

2.  Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study.

Authors:  Maja Skov Kragsnaes; Shaun Theodor Sødergren; Jens Kjeldsen; Hans Christian Horn; Heidi Lausten Munk; Jens Kristian Pedersen; Camilla Schufri Klinkby; Maarten de Wit; Nanna Gram Ahlmark; Tine Tjørnhøj-Thomsen; Torkell Ellingsen
Journal:  BMJ Open       Date:  2021-03-08       Impact factor: 2.692

3.  Smart About Meds (SAM): a pilot randomized controlled trial of a mobile application to improve medication adherence following hospital discharge.

Authors:  Bettina Habib; David Buckeridge; Melissa Bustillo; Santiago Nicolas Marquez; Manish Thakur; Thai Tran; Daniala L Weir; Robyn Tamblyn
Journal:  JAMIA Open       Date:  2021-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.